Resources from the same session
4441 - KEYNOTE-022 Part 3: Phase 2 Randomized Study of 1L Dabrafenib (D) and Trametinib (T) Plus Pembrolizumab (Pembro) or Placebo (PBO) for BRAF-Mutant Advanced Melanoma
Presenter: Paolo Ascierto
Session: Proffered paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
3062 - OpACIN-neo – A Multicenter Phase 2 Study to identify the Optimal neo-Adjuvant Combination scheme of Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Christian Blank
Session: Proffered paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
6257 - Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma
Presenter: Georgina Long
Session: Proffered paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Proffered paper session - Melanoma and other skin tumours - Invited Discussant one LBA TBC, LBA42 and LBA43
Presenter: Caroline Robert
Session: Proffered paper session - Melanoma and other skin tumours
Resources:
Slides
Webcast
3610 - Overall survival at 4 years of follow-up in a phase 3 trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
Presenter: F. Hodi
Session: Proffered paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast